Company: ZVRA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001434647-25-000011
Chunk: 50

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
,313 1,049 5,234 2,248 Total other (expense) income(5,120)(5,919)146,270 1,815 (Loss) income before income taxes(977)(33,225)74,012 (69,772)Income tax benefit (expense)433 — (2,948)— Net (loss) income$(544)$(33,225)$71,064 $(69,772)Net (loss) income per share of common stock:Basic$(0.01)$(0.69)$1.20 $(1.59)Diluted$(0.01)$(0.69)$1.16 $(1.59)Weighted-average shares of common stock outstanding:Basic55,951,57247,808,81754,949,48343,843,851Diluted55,951,57247,808,81756,782,76343,843,851

See accompanying notes to unaudited condensed consolidated financial statements.

5

Table of Contents

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(in thousands)

Three months ended September 30,Nine months ended September 30,2025202420252024Net (loss) income$(544)$(33,225)$71,064 $(69,772)Other comprehensive income (loss):Foreign currency translation adjustment12 (536)(3,047)(72)Other comprehensive income (loss):12 (536)(3,047)(72)Comprehensive (loss) income$(532)$(33,761)$68,017 $(69,844)

See accompanying notes to unaudited condensed consolidated financial statements.

6

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands)

AdditionalTreasuryOtherTotalCommonPaid-inStock,AccumulatedComprehensiveStockholders'StockCapitalat costDeficitIncome (Loss)EquityBalance as of January 1, 2025$5 $555,302 $(10,983)$(505,289)$631 $39,666 Net loss— — — (3,099)— (3,099)Stock-based compensation expense— 3,115